Search
Etravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalIn 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development … well as notification of health care providers.
Ferric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigationalFerric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells.
BCG vaccine
go.drugbank.com/drugs/DB12768ApprovedInvestigationalWithdrawnBCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
Valoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[A252797] As opposed to these therapies, valoctocogene roxaparvovec offers the advantage of continuous and measurable steady-state levels of coagulation factor VIII.[A252807] … [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States.
Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigationalA related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by shortened and partially functional dystrophin protein production. … Casimersen was granted accelerated FDA approval on February 25, 2021, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with casimersen; this approval is contingent
NOV-002
go.drugbank.com/drugs/DB05393InvestigationalNOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. … It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.
Sar9, Met (O2)11-Substance P
go.drugbank.com/drugs/DB05875InvestigationalSar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.
Clothiapine
go.drugbank.com/drugs/DB13256ApprovedClothiapine has been approved in European countries and is an atypical antipsychotic, shown to be useful in some treatment-resistant patients.
Probucol
go.drugbank.com/drugs/DB01599ApprovedInvestigationalWithdrawnA drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
Benzbromarone
go.drugbank.com/drugs/DB12319ApprovedWithdrawnBenzbromarone has been used in trials studying the basic science and treatment of Heart Failure, Hyperuricemia, Chronic Kidney Disease, Abnormal Renal Function, and Gout and Asymptomatic Hyperuricemia.